Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €58.57 EUR
Change Today +0.50 / 0.86%
Volume 89.0
BRM On Other Exchanges
Symbol
Exchange
New York
Mexico
Sao Paulo
Frankfurt
As of 9:49 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BRM) Snapshot

Open
€58.28
Previous Close
€58.07
Day High
€58.64
Day Low
€58.26
52 Week High
07/21/15 - €65.30
52 Week Low
08/8/14 - €35.92
Market Cap
97.7B
Average Volume 10 Days
1.3K
EPS TTM
--
Shares Outstanding
1.7B
EX-Date
07/1/15
P/E TM
--
Dividend
€1.47
Dividend Yield
2.16%
Current Stock Chart for BRISTOL-MYERS SQUIBB CO (BRM)

bristol-myers squibb co (BRM) Details

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company’s products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; and Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. Its products also comprise Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia for use in treating patients with moderately to severely active rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. In addition, it is developing Opdivo, a human monoclonal antibody, which is in Phase III trials for non-small cell lung cancer, renal cell cancer, and melanoma; Beclabuvir, a non-nucleoside NS5B inhibitor that is in Phase III development for the treatment of HCV; Elotuzumab, a humanized monoclonal antibody, which is in Phase III trials for the treatment of multiple myeloma; and BMS-663068, an investigational compound that is being studied in HIV-1. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

25,000 Employees
Last Reported Date: 02/13/15
Founded in 1887

bristol-myers squibb co (BRM) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $916.0K
Executive Chairman, Officer, Ex-Officio Membe...
Total Annual Compensation: $1.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $910.5K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $875.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $849.8K
Compensation as of Fiscal Year 2014.

bristol-myers squibb co (BRM) Key Developments

Bristol-Myers Squibb Plans to Expand its Manufacturing Facility in Humacao, Puerto Rico

Bristol-Myers Squibb has announced investments of USD 165 million to expand its manufacturing facility in Humacao, Puerto Rico. The company's expansion plans will facilitate the production of type 2 diabetes medicines.

FDA Approves Bristol-Myers Squibb Company's Daklinza (daclatasvir) for the Treatment of Patients with Chronic Hepatitis C Genotype 3

Bristol-Myers Squibb Company announced that Daklinza™ (daclatasvir), an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug Administration (FDA). This approval marks the first time patients with chronic hepatitis C virus (HCV) genotype 3 have a 12-week, once-daily, all-oral treatment option. Daklinza is indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection. Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving this regimen. The recommended dosage of Daklinza is 60 mg in combination with sofosbuvir for 12 weeks. The pivotal Phase III open-label ALLY-3 clinical trial enrolled 152 patients with chronic HCV genotype 3 infection and compensated liver disease (101 treatment-naïve patients and 51 treatment-experienced patients). The co-primary endpoints were sustained virologic response rates 12 weeks after completing therapy (SVR12) in each treatment group. The full study design is outlined below. In the trial the Daklinza plus sofosbuvir regimen demonstrated SVR12 in 90% of treatment-naïve and 86% of treatment-experienced chronic HCV genotype 3 patients. SVR12 rates were higher (96%) in genotype 3 patients without cirrhosis, regardless of treatment history. In the more difficult-to-treat patients with cirrhosis, SVR12 rates were reduced (63%). These SVR12 rates were achieved with 12 weeks of therapy without the use of ribavirin. In the pivotal Phase III trial, there were no treatment-related serious adverse events (SAEs) and no discontinuations due to adverse events (AEs). The most common treatment-related AEs at a frequency of =5% were headache (14%), fatigue (14%), nausea (8%) and diarrhea (5%).

Bristol-Myers Squibb Company Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Year 2015

Bristol-Myers Squibb Company reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $4,163 million against $3,889 million a year ago. Earnings before income taxes were $52 million against $448 million a year ago. Net loss attributable to company was $130 million against net earnings attributable to the company of $333 million a year ago. Loss per basic and diluted share was $0.08 against earnings per basic and diluted share of $0.20 diluted per share a year ago. The company reported non-GAAP net earnings attributable to the company of $890 million, or $0.53 per share compared to $798 million, or $0.48 per share, for the same period in 2014. For the six months, the company reported total revenue of $8,204 million against $7,700 million a year ago. Earnings before income taxes were $1,500 million against $1,433 million a year ago. Net earnings attributable to company were $1,056 million against $1,270 million a year ago. Earnings per basic and diluted share were $0.63 against $0.76 diluted per share a year ago. Non-GAAP net earnings were $2,083 million or $1.24 diluted per share against $1,564 million or $0.94 diluted per share a year ago. The company is increasing its 2015 GAAP EPS guidance range from $0.96 to $1.06 to $1.02 to $1.12. The company is also increasing its non-GAAP EPS guidance range from $1.60 to $1.70 to $1.70 to $1.80. Both GAAP and non-GAAP guidance assume current exchange rates and that the R&D tax credit will be extended by Congress in 2015. Key revised 2015 non-GAAP line-item guidance assumptions include: worldwide revenues between $15.5 and $15.9 billion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BRM:GR €58.57 EUR +0.50

BRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $71.39 USD +0.16
Allergan plc $336.25 USD -3.25
Eli Lilly & Co $85.03 USD -0.65
Medtronic PLC $77.11 USD -0.355
Novo Nordisk A/S kr400.00 DKK +7.00
View Industry Companies
 

Industry Analysis

BRM

Industry Average

Valuation BRM Industry Range
Price/Earnings 60.2x
Price/Sales 6.5x
Price/Book 7.1x
Price/Cash Flow 59.9x
TEV/Sales 5.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRISTOL-MYERS SQUIBB CO, please visit www.bms.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.